

# OPALE - Survey of the therapeutic management of rheumatoid arthritis in France in 2006

Head :Bregman Bruno, Bristol-Myers Squibb  
Schmidely Nathalie, Bristol-Myers Squibb

Last update : 01/23/2015 | Version : 2 | ID : 122

## General

### Identification

Detailed name Survey of the therapeutic management of rheumatoid arthritis in France in 2006

Sign or acronym OPALE

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL 833542 version 11

### General Aspects

Medical area Rheumatology

Health determinants Genetic

Others (details) rheumatoid arthritis

Keywords Rheumatoid arthritis, epidemiology, DMARD, treatments

### Scientific investigator(s) (Contact)

Name of the director Bregman

Surname Bruno

Address 3, rue J. Monier - 92500 Rueil Malmaison

Phone +33 (0)1 58 83 60 00

Email bruno.bregman@bms.com

Unit Bristol-Myers Squibb

Name of the director Schmidely

Surname Nathalie

Address	3, rue J. Monier - 92500 Rueil Malmaison
Phone	+33 (0)1 58 83 60 00
Email	nathalie.schmidely@bms.com
Unit	Bristol-Myers Squibb

## Collaborations

## Funding

Funding status	Private
----------------	---------

Details	Bristol-Myers Squibb
---------	----------------------

## Governance of the database

Sponsor(s) or organisation(s) responsible	Bristol-Myers Squibb (BMS)
Organisation status	Private

## Additional contact

## Main features

## Type of database

Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Random sampling in clusters

## Database objective

Main objective	Describe the therapeutic practice used by French rheumatologists in patients suffering from rheumatoid arthritis patients, and describe the treatment patterns used, in a general manner and according to the patients' and disease characteristics.
----------------	--

Inclusion criteria	Register Part: M/F $\geq 18$ years, with a mild to severe rheumatoid arthritis currently treated or not treated with either symptomatic agents or DMARD (disease-modifying anti-rheumatism drug treatment) (biological or non-biological), seen in rheumatology clinic visit. Detailed Study Part: patients eligible for the register part, currently treated or initiating a first DMARD (disease-modifying anti-rheumatism drug treatment) (biological or non-biological) at the time of inclusion in the study
<b>Population type</b>	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	Metropolitan France
<b>Data collection</b>	
<b>Dates</b>	
Date of first collection (YYYY or MM/YYYY)	2006
Date of last collection (YYYY or MM/YYYY)	2006
<b>Size of the database</b>	
Size of the database (number of individuals)	[1000-10 000[ individuals
Details of the number of individuals	1600
<b>Data</b>	
Database activity	Data collection completed
Type of data collected	Clinical data

## Biological data

Clinical data (detail)

Direct physical measures

Biological data (detail)

ESR, CRP, Rheumatoid factor, HLA DR4, Anti CCP

Presence of a biobank

No

Health parameters studied

Health event/morbidity

## Procedures

Data collection method

Paper or electronic form

Participant monitoring

No

Links to administrative sources

No

## Promotion and access

### Promotion

Link to the document

<http://tinyurl.com/PUBMED-OPALE>

Description

Link to the document

<http://tinyurl.com/HAL-OPALE>

Description

### Access

Terms of data access (charter for data provision, format of data, availability delay)

Publications

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only